Literature DB >> 18628780

Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus.

Golam M I Chowdhury1, Mounira Banasr, Robin A de Graaf, Douglas L Rothman, Kevin L Behar, Gerard Sanacora.   

Abstract

Riluzole is believed to modulate glutamatergic function by reducing glutamate release and facilitating astroglial uptake. We measured (13)C labeling in metabolites in prefrontal cortex and hippocampus during a 10 mins infusion of [1-(13)C]glucose in urethane anesthetized rats treated with riluzole (21 days, 4 mg/kg per day, i.p.) or saline. Total and (13)C concentrations of metabolites were determined in extracts using (1)H-[(13)C] NMR spectroscopy. In prefrontal cortex (P<0.05) and hippocampus (P<0.05) riluzole increased (13)C labeling over saline in glutamate-C4 (to 112% and 130%), GABA-C2 (to 142% and 171%), and glutamine-C4 (to 118% and 233%) without affecting total metabolite levels (P>0.2). Our findings indicate that contrary to expectation chronic riluzole enhanced glucose oxidative metabolism and glutamate/glutamine cycling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628780      PMCID: PMC2739056          DOI: 10.1038/jcbfm.2008.78

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  19 in total

Review 1.  Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis.

Authors:  Leif Hertz; Liang Peng; Gerald A Dienel
Journal:  J Cereb Blood Flow Metab       Date:  2006-07-12       Impact factor: 6.200

2.  Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons.

Authors:  C S Huang; J H Song; K Nagata; J Z Yeh; T Narahashi
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

3.  Pro-survival signalling from the NMDA receptor.

Authors:  G E Hardingham
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

4.  In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during.

Authors:  N R Sibson; G F Mason; J Shen; G W Cline; A Z Herskovits; J E Wall; K L Behar; D L Rothman; R G Shulman
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

5.  Neuroglial metabolism in the awake rat brain: CO2 fixation increases with brain activity.

Authors:  Gülin Oz; Deborah A Berkich; Pierre-Gilles Henry; Yuping Xu; Kathryn LaNoue; Susan M Hutson; Rolf Gruetter
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

Review 6.  The pharmacology and mechanism of action of riluzole.

Authors:  A Doble
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

Review 7.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

Authors:  S-J Wang; K-Y Wang; W-C Wang
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

9.  Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.

Authors:  S Kalra; N R Cashman; A Genge; D L Arnold
Journal:  Neuroreport       Date:  1998-06-01       Impact factor: 1.837

10.  Riluzole inhibits the persistent sodium current in mammalian CNS neurons.

Authors:  A Urbani; O Belluzzi
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

View more
  25 in total

1.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

2.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 3.  Applications of NMR spectroscopy to systems biochemistry.

Authors:  Teresa W-M Fan; Andrew N Lane
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2016-02-06       Impact factor: 9.795

Review 4.  The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

5.  The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo.

Authors:  Golam M I Chowdhury; Lihong Jiang; Douglas L Rothman; Kevin L Behar
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-30       Impact factor: 6.200

Review 6.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

7.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 8.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  In situ 3D magnetic resonance metabolic imaging of microwave-irradiated rodent brain: a new tool for metabolomics research.

Authors:  Robin A de Graaf; Golam M I Chowdhury; Peter B Brown; Douglas L Rothman; Kevin L Behar
Journal:  J Neurochem       Date:  2009-02-07       Impact factor: 5.372

10.  Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole.

Authors:  A C Pereira; J D Gray; J F Kogan; R L Davidson; T G Rubin; M Okamoto; J H Morrison; B S McEwen
Journal:  Mol Psychiatry       Date:  2016-03-29       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.